NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
NanoViricides (NYSE:NNVC) announced its presentation at the MicroCap Conference 2025 in Atlantic City on January 29, highlighting their lead drug candidate NV-387. The company is advancing towards Phase II clinical trials for MPOX disease treatment in the African Region.
NV-387 has demonstrated broad-spectrum antiviral activity, showing superior results compared to existing treatments in animal models against multiple viruses including Influenza, MPox, RSV, and SARS-CoV-2. The drug mimics a host-side feature used by 90-95% of human pathogenic viruses, making it difficult for viruses to develop resistance.
The company estimates the market size for NV-387 indications to exceed $10 billion. The presentation, scheduled for 11:00 AM at The Borgata Hotel, will be delivered by President and Executive Chairman Anil R. Diwan, PhD, covering updates on the company's drug pipeline and technologies available for licensing.
NanoViricides (NYSE:NNVC) ha annunciato la sua presentazione alla MicroCap Conference 2025 ad Atlantic City il 29 gennaio, evidenziando il loro principale candidato farmacologico NV-387. L'azienda sta avanzando verso la fase II delle sperimentazioni cliniche per il trattamento della malattia MPOX nella regione africana.
NV-387 ha dimostrato un'ampia attività antivirale, mostrando risultati superiori rispetto ai trattamenti esistenti in modelli animali contro diversi virus tra cui Influenza, MPox, RSV e SARS-CoV-2. Il farmaco mimica una caratteristica del lato ospite utilizzata dal 90-95% dei virus patogeni umani, rendendo difficile per i virus sviluppare resistenza.
L'azienda stima che la dimensione del mercato per le indicazioni di NV-387 supererà $10 miliardi. La presentazione, programmata per le 11:00 presso il Borgata Hotel, sarà tenuta dal Presidente e Presidente Esecutivo Anil R. Diwan, PhD, e coprirà aggiornamenti sul pipeline farmacologico dell'azienda e sulle tecnologie disponibili per la licenza.
NanoViricides (NYSE:NNVC) anunció su presentación en la MicroCap Conference 2025 en Atlantic City el 29 de enero, destacando su principal candidato a fármaco NV-387. La empresa avanza hacia la fase II de ensayos clínicos para el tratamiento de la enfermedad MPOX en la región africana.
NV-387 ha demostrado una amplia actividad antiviral, mostrando resultados superiores en comparación con los tratamientos existentes en modelos animales contra múltiples virus, incluyendo Influenza, MPox, RSV y SARS-CoV-2. El fármaco imita una característica del lado del hospedador utilizada por el 90-95% de los virus patógenos humanos, lo que dificulta que los virus desarrollen resistencia.
La empresa estima que el tamaño del mercado para las indicaciones de NV-387 superará $10 mil millones. La presentación, programada para las 11:00 AM en el Borgata Hotel, será dada por el Presidente y Presidente Ejecutivo Anil R. Diwan, PhD, cubriendo actualizaciones sobre el pipeline de medicamentos de la empresa y las tecnologías disponibles para licenciar.
나노바이러사이드(NYSE:NNVC)는 1월 29일 애틀랜틱 시티에서 열리는 마이크로캡 컨퍼런스 2025에서 주요 약물 후보 NV-387에 대한 발표를 안내했습니다. 이 회사는 아프리카 지역의 MPOX 질병 치료를 위한 임상 2상 시험으로 나아가고 있습니다.
NV-387은 광범위한 항바이러스 활성을 보여주었으며, 인플루엔자, MPox, RSV, SARS-CoV-2 등 여러 바이러스에 대해 기존 치료법보다 우수한 결과를 보였습니다. 이 약물은 인간 병원체 바이러스의 90-95%가 사용하는 숙주 측 특징을 모방하여 바이러스가 내성을 개발하기 어렵게 만듭니다.
회사는 NV-387의 적응증에 대한 시장 규모가 $10억 달러를 초과할 것으로 추정하고 있습니다. 11:00 AM에 Borgata Hotel에서 예정되어 있는 이 발표는 회장인 Anil R. Diwan 박사가 진행하며, 회사의 약물 파이프라인 및 라이센스를 위한 기술에 대한 업데이트를 다룰 예정입니다.
NanoViricides (NYSE:NNVC) a annoncé sa présentation lors de la MicroCap Conference 2025 à Atlantic City le 29 janvier, mettant en avant leur principal candidat médicamenteux NV-387. L'entreprise progresse vers les essais cliniques de phase II pour le traitement de la maladie MPOX dans la région africaine.
NV-387 a démontré une activité antivirale à large spectre, montrant des résultats supérieurs par rapport aux traitements existants dans des modèles animaux contre plusieurs virus, y compris la grippe, MPox, RSV et SARS-CoV-2. Le médicament imite une caractéristique côté hôte utilisée par 90-95% des virus pathogènes humains, rendant difficile pour les virus de développer une résistance.
L'entreprise estime que la taille du marché pour les indications de NV-387 dépassera 10 milliards de dollars. La présentation, prévue à 11h00 au Borgata Hotel, sera faite par le Président et Président Exécutif Anil R. Diwan, PhD, et couvrira des mises à jour sur le pipeline de médicaments de l'entreprise et les technologies disponibles pour la licence.
NanoViricides (NYSE:NNVC) hat seine Präsentation auf der MicroCap Conference 2025 in Atlantic City am 29. Januar angekündigt, wobei das Hauptarzneimittelkandidat NV-387 hervorgehoben wird. Das Unternehmen arbeitet auf die Phase-II-Klinikstudien zur Behandlung von MPOX-Krankheit in der afrikanischen Region hin.
NV-387 hat eine breite antivirale Aktivität gezeigt und überlegene Ergebnisse im Vergleich zu bestehenden Behandlungen in Tiermodellen gegen mehrere Viren, darunter Influenza, MPox, RSV und SARS-CoV-2, erzielt. Das Medikament ahmt ein Merkmal der Wirtsseite nach, das von 90-95% der menschlichen pathogenen Viren genutzt wird, was es den Viren schwierig macht, Resistenzen zu entwickeln.
Das Unternehmen schätzt, dass die Marktgröße für NV-387-Anzeigen 10 Milliarden USD übersteigen wird. Die Präsentation, die um 11:00 Uhr im Borgata Hotel stattfinden wird, wird von Präsident und Executive Chairman Anil R. Diwan, PhD, gehalten und umfasst Updates über die Medikamentenpipeline des Unternehmens und Technologien, die zur Lizenzierung verfügbar sind.
- None.
- None.
SHELTON, CT / ACCESS Newswire / January 29, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it is presenting today, January 29, at 11am at the MicroCap Conference 2025 in Atlantic City, NJ.
Event Information:
Event | NanoViricides Presentation at the MicroCap Conference, Atlantic City |
Day & Date | Wednesday, January 29, 2025 |
Time | 11:00 am to 11:30 am |
Location | The Borgata Hotel, Atlantic City, NJ |
Admission | Open Admission Policy, Everyone is Welcome |
NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease. The Company has announced that it has engaged a CRO for conducting the Phase II clinical trials in the African Region.
There is currently no treatment for hMPXV infection that causes the MPOX disease. Tecovirimat, (TPOXX®, SIGA) approved under "Animal Rule" by the US FDA, failed in a clinical trial to demonstrate effectiveness for treating MPOX infection in a clinical trial.
MPox Clade 1 and 1b infections have caused a continuing pandemic in the Africa that led to WHO declaring a Public Health Emergency of International Concern (PHEIC) in August 2024.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Technologies available for licensing.
The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90
In light of the concerns regarding H5N1 Bird Flu and its potential spread, NV-387 is one of the most promising candidates that can respond to an Influenza pandemic. The Influenza virus would be unable to escape the NV-387 drug treatment because this drug mimics the feature on the host-side that all Influenza viruses continue to use for causing an infection, even as they evolve rapidly in the field.
NV-387 has demonstrated activity substantially superior to each of oseltamivir (Tamiflu®), peramivir (Rapivab®), and baloxavir (Xofluza®) in lethal animal models of Influenza A lung viral infection. These approved drugs as well as vaccines and antibodies are readily escaped by the virus as it evolves in the field.
NV-387 has also shown strong activity in lethal animal model studies for MPox and Smallpox treatment developments. There is no drug for the treatment of MPox infection at present.
NV-387 has demonstrated cure of lethal RSV infection in animal model studies. There is no drug for the treatment of RSV infection at present, except for the last resort toxic drug ribavirin.
NV-387 has demonstrated strong activity against coronavirus lethal animal models for SARS-CoV-2 infection (COVID-19).
In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought after technology by Pharma companies.
The overall market size of NV-387 indications is estimated to be well in excess of
This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
The Microcap Conference is the largest independent microcap event in the U.S., featuring three days of one-on-one investor meetings, company presentations, expert discussions, and nonstop networking - all set against the vibrant backdrop of the Borgata in Atlantic City.
Focused on high-quality companies, the conference provides unmatched access to our investor network, with participation fees and an event format that reflects our commitment to excellence.
With an open admission policy, everyone is welcome. Plus, attendees can bring a guest to enjoy the entertainment and social activities alongside the conference experience.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key advantages of NanoViricides' NV-387 drug candidate over existing antiviral treatments?
When will NanoViricides (NNVC) begin Phase II trials for MPOX treatment?
What is the estimated market size for NanoViricides' NV-387 drug applications?
Which viral infections has NV-387 shown effectiveness against in animal studies?
What is the significance of NNVC's presentation at the 2025 MicroCap Conference?
